Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial
Authors
Keywords
-
Journal
CANCER SCIENCE
Volume 110, Issue 10, Pages 3049-3060
Publisher
Wiley
Online
2019-08-08
DOI
10.1111/cas.14165
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
- (2016) Yu Sawada et al. OncoImmunology
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Clinical Trial of Multiple Peptide Vaccination for Advanced Head and Neck Cancer Patients Revealed Induction of Immune Responses and Improved OS
- (2014) Y. Yoshitake et al. CLINICAL CANCER RESEARCH
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes
- (2014) YU SAWADA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Therapeutic vaccines for cancer: an overview of clinical trials
- (2014) Ignacio Melero et al. Nature Reviews Clinical Oncology
- PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines
- (2013) J. Fourcade et al. CANCER RESEARCH
- Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer
- (2013) A. Aruga et al. CLINICAL CANCER RESEARCH
- Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
- (2013) YOSHITAKA TADA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
- (2013) Richard A. Morgan et al. JOURNAL OF IMMUNOTHERAPY
- HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial
- (2013) Mariette I E van Poelgeest et al. Journal of Translational Medicine
- Colorectal cancer
- (2013) Hermann Brenner et al. LANCET
- Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion
- (2013) Yared Hailemichael et al. NATURE MEDICINE
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer
- (2013) YU SAWADA et al. ONCOLOGY REPORTS
- Peptide intra-tumor injection for cancer immunotherapy
- (2013) Daisuke Nobuoka et al. Human Vaccines & Immunotherapeutics
- Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy
- (2012) Daisuke Nobuoka et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
- (2012) Steffen Walter et al. NATURE MEDICINE
- HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells
- (2011) Toshiaki Yoshikawa et al. CANCER SCIENCE
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
- (2010) Maria R Parkhurst et al. MOLECULAR THERAPY
- Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
- (2009) L. A. Johnson et al. BLOOD
- Biased usage of BV gene families of T-cell receptors of WT1 (Wilms’ tumor gene)-specific CD8+T cells in patients with myeloid malignancies
- (2009) Yukie Tanaka-Harada et al. CANCER SCIENCE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Differential expression of heat shock protein 105 in melanoma and melanocytic naevi
- (2008) Faith Chengetayi Muchemwa et al. MELANOMA RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search